Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 5/20 | 0.42 |
| ▸ | ESR1 | P03372 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | XBP1 | P17861 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1149294 | 0.84 | TDP1 (0.43) | SMN1; SMN2MAPK1TDP1NR1I2PTGS1 | |
| SCHEMBL186927 | 0.74 | APP (0.51) | APPESR1SMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL186928 | 0.74 | APP (0.51) | APPESR1SMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL4448687 | 0.73 | SMN1; SMN2 (0.52) | APPESR1SMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL28030905 | 0.72 | MAPT (0.50) | SMN1; SMN2MAPK1L3MBTL1NPC1HPGD | |
| SCHEMBL4448685 | 0.71 | APP (0.48) | APPESR1SMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL1673397 | 0.69 | ESR1 (0.44) | ESR1SMN1; SMN2NPSR1 | |
| SCHEMBL23431893 | 0.68 | SRC (0.41) | MAPK1HPGDTDP1NR1I2PTGS1 | |
| SCHEMBL21606671 | 0.68 | SRC (0.41) | MAPK1HPGDTDP1NR1I2PTGS1 | |
| SCHEMBL11689234 | 0.68 | L3MBTL1 (0.55) | APPESR1SMN1; SMN2MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722923-B2 | Conjugates for treating neurodegenerative diseases and disorders | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2014-05-13 | — | — | US | disclosed |
| US-20120277310-A1 | NOVEL CONJUGATES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | BAR-ILAN UNIVERSITY (IL) | 2012-11-01 | — | — | US | disclosed |
| EP-2252578-B1 | CONJUGATES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | UNIV RAMOT (IL) | 2012-08-01 | — | — | EP | disclosed |
| US-8207369-B2 | Conjugates for treating neurodegenerative diseases and disorders | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2012-06-26 | — | — | US | disclosed |
| US-20110034553-A1 | NOVEL CONJUGATES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277310-A1 | NOVEL CONJUGATES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | SLC18A2, GABRB2, SLC6A13 | APP 207/4885ESR1 4113/4885SMN1; SMN2 55/4885 |
| US-20110034553-A1 | NOVEL CONJUGATES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | SLC18A2, SNCA, SLC6A13 | APP 229/4885ESR1 4297/4885SMN1; SMN2 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.